Roche-Genentech to develop in-house digital therapeutic. UHC. Livongo.

Issue 023.

Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 71 percent open rate. Here's what's happening this week:

A warm welcome to all of the new E&O enterprise subscribers! And a reminder: If your company has an enterprise subscription, any and all of your coworkers are entitled to an E&O membership. So feel free to have your colleagues send me an email if they'd like full access. For those of you looking to make E&O available to your entire team or company, head on over to the E&O pricing page here for more info.
Better Therapeutics published its fifth study: This one assesses economic impact of the company's digital therapeutics for type 2 diabetes and hypertension. Read this summary or the full study here.
Biofourmis announced a second FDA 510(k) clearance (first one was in May), this time for its Biovitals

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Roche-Genentech to develop in-house digital therapeutic. UHC. Livongo.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.